(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Remote Headphones: Improve Your Sound Insight - 2Ancient Pompeii construction site reveals the process for creating Roman concrete
- 35 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- 4Embrace Effortlessness: Moderation and Cleaning up Tips
- 5Which game do you cherish observing live? Vote!
- Car Investigation: A Survey of \Past the Outside\ Car
- Germany's first Omani LNG shipments arrive despite Middle East disruptions
- Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
- RFK Jr. guts the US childhood vaccine schedule despite its decades-long safety record
- Nations for Youngsters to Visit
- Fake new headlights rule steer Australian drivers astray
- Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat!
- Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
- The most effective method to Distinguish the Best Material Organization in Your Space
